Physicochemical and biopharmaceutical characterization of new sulfonamide derivatives of gallic acid
British Journal of Pharmacy, 2022 Gallic acid (GA) is known for its antioxidant activity which is restricted due to its low oral permeability. In this project the carboxylic group of (GA) was substituted with sulfonamide group and hydroxyl groups were methylated which resulted ...
Dania Hussein Alhyari +7 more
doaj +1 more source
Association of ABCB1, 5-HT3B receptor and CYP2D6 genetic polymorphisms with ondansetron and metoclopramide antiemetic response in Indonesian cancer patients treated with highly emetogenic chemotherapy. [PDF]
, 2011 Our study shows that in Indonesian cancer patients treated with highly cytostatic emetogenic, carriership of the CTG haplotype of the ABCB1 gene is related to an increased risk of delayed chemotherapy-induced nausea and ...
Baak-Pablo, Renee F +8 more
core +2 more sources
Assessment of Activity Levels for CYP2D6*1, CYP2D6*2, and CYP2D6*41 Genes by Population Pharmacokinetics of Dextromethorphan [PDF]
Clinical Pharmacology & Therapeutics, 2010 The pharmacokinetics of dextromethorphan (DM) is markedly influenced by cytochrome P450 2D6 (CYP2D6) enzyme polymorphisms. The aim of this study was to quantify the effects of the CYP2D6*1, *2, and *41 variants on DM metabolism in vivo and to identify other sources of pharmacokinetic variability.
Abduljalil, K +8 more
openaire +3 more sources
Dietary-Driven Gene Expansion. [PDF]
Clin Pharmacol TherGene duplication has been shown to drive molecular evolution, with dietary pressures expanding detoxification genes across species. In humans, CYP2D6 gene duplications enhance alkaloid and drug metabolism, reflecting ancient dietary adaptations. Similarly, tobacco‐feeding aphids amplify CYP6CY3 for nicotine and insecticide resistance, and as recently ...
Ingelman-Sundberg M.
europepmc +2 more sources
Physiology-based IVIVE predictions of tramadol from in vitro metabolism data [PDF]
, 2014 To predict the tramadol in vivo pharmacokinetics in adults by using in vitro metabolism data and an in vitro-in vivo extrapolation (IVIVE)-linked physiologically-based pharmacokinetic (PBPK) modeling and simulation approach (SimcypA (R)).
Allegaert, Karel +10 more
core +1 more source
Enhanced Characterization of Drug Metabolism and the Influence of the Intestinal Microbiome: A Pharmacokinetic, Microbiome, and Untargeted Metabolomics Study. [PDF]
, 2020 Determining factors that contribute to interindividual and intra-individual variability in pharmacokinetics (PKs) and drug metabolism is essential for the optimal use of drugs in humans.
Alhaja, Maher +8 more
core +1 more source
Frontiers in Pharmacology, 2023 CYP2D6 is one of the most polymorphic drug-metabolizing enzymes in the liver. While genetic CYP2D6 variants serve as clinical biomarkers to predict CYP2D6 activity, large inter-person variability in CYP2D6 expression remains unaccounted for.
Joseph M. Collins +3 more
doaj +1 more source
Pharmacogenetics of ophthalmic topical β-blockers [PDF]
, 2008 Glaucoma is the second leading cause of blindness worldwide. The primary glaucoma risk factor is elevated intraocular pressure. Topical β-blockers are affordable and widely used to lower intraocular pressure.
McCarty, Catherine A. +4 more
core +1 more source
Неотложная медицинская помощь, 2020 Relevance. One of the key components of the accelerated recovery protocols (ARP), in addition to minimizing the surgical approach, is an adequate postoperative analgesia.
A. A. Muradyan +7 more
doaj +1 more source
Медицинский совет, 2022 Introduction. Despite the huge number of modern recommendations for the treatment of patients with liver cirrhosis, there is still no clear scheme for prescribing non-selective beta-blockers.Aim. To evaluate effect of polymorphic markers CYP2D6*3, CYP2D6*
A. I. Parusov +6 more
doaj +1 more source